\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ \\ \ \(0\)\
\-\ no\\ abnormalities\\.\ \(11\)\
\-\ labs\\:\ \(4\)\
\-\ fungal\\,\\ acid\\-fast\\,\\ and\\ gram\\ stains\\ showed\\ no\\ \\ organisms\\.\\ \\ \ \(0\)\
\-\ pleural\\ fluid\\ analysis\\ was\\ suspicious\\ for\\ malignancy\\.\ \(0\)\
\-\ histopathologic\\ analysis\\ of\\ tissue\\ samples\\ of\\ all\\ three\\ right\\ lung\\ lobes\\ including\\ mediastinal\\ lymph\\ nodes\\ revealed\\ extensive\\ lymphovascular\\ invasion\\,\\ focal\\ areas\\ of\\ necrosis\\,\\ and\\ several\\ areas\\ with\\ signet\\-ring\\ cells\\.\ \(0\)\
\-\ the\\ patient\\ was\\ initially\\ treated\\ for\\ pneumonia\\ based\\ on\\ her\\ symptoms\\ and\\ the\\ findings\\ on\\ chest\\ x\\-ray\\.\\ \\ further\\ evaluation\\ was\\ completed\\ after\\ recurrence\\ of\\ symptoms\\ within\\ one\\ month\\ of\\ therapy\\.\\ \\ vats\\ and\\ mediastinoscopy\\ were\\ performed\\ after\\ bronchoalveolar\\ lavage\\ yielded\\ cells\\ suspicious\\ for\\ malignancy\\.\\ \\ a\\ whole\\ body\\ pet\\ scan\\ and\\ brain\\ mri\\ were\\ performed\\ and\\ did\\ not\\ reveal\\ any\\ evidence\\ of\\ distant\\ metastases\\.\\ \\ chemotherapy\\ was\\ initiated\\ and\\ the\\ patient\\ later\\ underwent\\ a\\ right\\-sided\\ pneumonectomy\\.\ \(0\)\
\-\ chest\\ pa\\/lat\\ revealed\\ increased\\ interstitial\\ markings\\ in\\ the\\ right\\ lower\\ lobe\\.\ \(0\)\
\-\ contrast\\ enhanced\\ chest\\ ct\\ revealed\\ diffuse\\ increased\\ interstitial\\ markings\\ involving\\ the\\ right\\ middle\\ and\\ lower\\ lobes\\,\\ pleural\\ thickening\\/scarring\\ of\\ the\\ posterior\\ right\\ lower\\ lobe\\,\\ and\\ a\\ small\\ right\\-sided\\ pleural\\ effusion\\.\ \(0\)\
\-\ adenocarcinoma\\ of\\ the\\ lung\ \(5\)\
\-\ lymphangitic\\ spread\\ of\\ malignancy\ \(3\)\
\-\ primary\\ malignancy\ \(8\)\
\-\ lymphoma\ \(373\)\
\-\ sjogrens\\ syndrome\ \(0\)\
\-\ lymphangioleiomyomatosis\ \(13\)\
\-\ pneumonia\\ \\(bacterial\\,\\ atypical\\,\\ viral\\)\ \(1\)\
\-\ collagen\\ vascular\\ disease\\ \\(sle\\,\\ ra\\)\ \(0\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ asbestosis\ \(10\)\
\-\ edema\\ \\(secondary\\ to\\ fluid\\ overload\\,\\ chf\\,\\ or\\ nephrotic\\ syndrome\\)\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 43\\-year\\-old\\ female\\ who\\ presented\\ with\\ a\\ 6\\-month\\ history\\ of\\ progressively\\ worsening\\ shortness\\ of\\ breath\\ with\\ exertion\\ during\\ her\\ 5\\-mile\\ runs\\.\\ \\ the\\ patient\\ also\\ complained\\ of\\ wheezing\\ but\\ denied\\ having\\ a\\ cough\\,\\ fevers\\,\\ chills\\,\\ or\\ weight\\ loss\\.\\ \\ this\\ patient\\ does\\ not\\ have\\ a\\ previous\\ history\\ of\\ any\\ chronic\\ illnesses\\ and\\ does\\ not\\ have\\ any\\ history\\ of\\ tobacco\\ use\\.\ \(0\)\
\-\ lung\\ cancer\\ must\\ be\\ ruled\\ out\\ in\\ any\\ patient\\ with\\ a\\ nonresolving\\ pneumonia\\.\\ \\ lung\\ cancer\\ has\\ surpassed\\ breast\\ cancer\\ in\\ becoming\\ the\\ leading\\ cause\\ of\\ cancer\\ death\\ in\\ women\\.\\ adenocarcinoma\\ accounts\\ for\\ 30\\-40\\%\\ of\\ lung\\ cancers\\ and\\ is\\ the\\ most\\ common\\ histologic\\ type\\.\\ \\ it\\ is\\ also\\ the\\ most\\ common\\ type\\ of\\ lung\\ cancer\\ in\\ non\\-smokers\\ \\(an\\ estimated\\ 10\\-15\\%\\ of\\ patients\\ diagnosed\\ with\\ lung\\ cancer\\ are\\ non\\-smokers\\)\\.\\ \\ the\\ most\\ common\\ sites\\ of\\ distant\\ metastases\\ are\\ the\\ brain\\,\\ bones\\ \\(most\\ commonly\\ vertebrae\\)\\,\\ liver\\,\\ adrenals\\,\\ and\\ skin\\.\\ \\ the\\ american\\ thoracic\\ society\\ recommends\\ measurement\\ of\\ a\\ cbc\\,\\ serum\\ electrolytes\\,\\ calcium\\,\\ alkaline\\ phosphatase\\,\\ albumin\\,\\ ast\\,\\ alt\\,\\ total\\ bilirubin\\,\\ and\\ creatinine\\ in\\ all\\ patients\\ with\\ lung\\ cancer\\.\\ \\ abnormal\\ lfts\\ should\\ be\\ followed\\ up\\ with\\ a\\ contrast\\-enhanced\\ ct\\ of\\ the\\ liver\\,\\ and\\ an\\ elevated\\ alkaline\\ phosphatase\\ or\\ calcium\\ level\\ should\\ be\\ followed\\ up\\ with\\ a\\ bone\\ or\\ pet\\ scan\\ to\\ detect\\ metastases\\ \\(there\\ is\\ conflicting\\ evidence\\ as\\ to\\ which\\ imaging\\ modality\\ has\\ greater\\ sensitivity\\)\\.\\ \\ stage\\ iv\\ disease\\ is\\ primarily\\ managed\\ with\\ chemotherapy\\ or\\ with\\ palliative\\ measures\\ for\\ symptomatic\\ relief\\,\\ and\\ the\\ five\\ year\\ survival\\ rate\\ is\\ less\\ than\\ 5\\%\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lung\\:\\ 0\\.03875004493524456\ \(0\)\
\-\ cancer\\:\\ 0\\.038481715950202264\ \(0\)\
\-\ non\\-smokers\\:\\ 0\\.03179010271391997\ \(0\)\
\-\ malignancy\\:\\ 0\\.02584806010020756\ \(0\)\
\-\ phosphatase\\:\\ 0\\.02190466770684265\ \(0\)\
\-\ metastases\\:\\ 0\\.02143287152667114\ \(0\)\
\-\ alkaline\\:\\ 0\\.02132376749111555\ \(0\)\
\-\ any\\:\\ 0\\.0210632879301158\ \(0\)\
\-\ pneumonia\\:\\ 0\\.02073765965887579\ \(0\)\
\-\ distant\\:\\ 0\\.019518109696584747\ \(0\)\
\-\ pleural\\:\\ 0\\.019481508015694496\ \(0\)\
\-\ markings\\:\\ 0\\.01854395686912242\ \(0\)\
\-\ pet\\:\\ 0\\.01755297488720222\ \(0\)\
\-\ lymphovascular\\:\\ 0\\.01725150376510078\ \(0\)\
\-\ mediastinoscopy\\:\\ 0\\.01725150376510078\ \(0\)\
\-\ thickening\\/scarring\\:\\ 0\\.01725150376510078\ \(0\)\
\-\ sjogrens\\:\\ 0\\.01725150376510078\ \(0\)\
\-\ 5\\-mile\\:\\ 0\\.01725150376510078\ \(0\)\
\-\ surpassed\\:\\ 0\\.01725150376510078\ \(0\)\
\-\ analysis\\:\\ 0\\.01702391508928342\ \(0\)\
\-\ interstitial\\:\\ 0\\.01636316804593684\ \(0\)\
\-\ calcium\\:\\ 0\\.01636316804593684\ \(0\)\
\-\ right\\-sided\\:\\ 0\\.016325352347652155\ \(0\)\
\-\ suspicious\\:\\ 0\\.01610582410244259\ \(0\)\
\-\ revealed\\:\\ 0\\.01610062949040759\ \(0\)\
\-\ acid\\-fast\\:\\ 0\\.015895051356959986\ \(0\)\
\-\ signet\\-ring\\:\\ 0\\.015895051356959986\ \(0\)\
\-\ nonresolving\\:\\ 0\\.015895051356959986\ \(0\)\
\-\ most\\:\\ 0\\.015442936530161063\ \(0\)\
\-\ pneumonectomy\\:\\ 0\\.015101577564184713\ \(0\)\
\-\ 6\\-month\\:\\ 0\\.015101577564184713\ \(0\)\
\-\ \\,\\:\\ 0\\.014833428247522595\ \(0\)\
\-\ lobes\\:\\ 0\\.01473840476210161\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.014448353990462775\ \(0\)\
\-\ nephrotic\\:\\ 0\\.014101918809261052\ \(0\)\
\-\ 43\\-year\\-old\\:\\ 0\\.014101918809261052\ \(0\)\
\-\ 30\\-40\\:\\ 0\\.014101918809261052\ \(0\)\
\-\ adrenals\\:\\ 0\\.014101918809261052\ \(0\)\
\-\ conflicting\\:\\ 0\\.014101918809261052\ \(0\)\
\-\ recommends\\:\\ 0\\.01374512515604392\ \(0\)\
\-\ samples\\:\\ 0\\.013443460420569833\ \(0\)\
\-\ cells\\:\\ 0\\.013410750270645781\ \(0\)\
\-\ common\\:\\ 0\\.013128770324597243\ \(0\)\
\-\ runs\\:\\ 0\\.012951651363268646\ \(0\)\
\-\ histopathologic\\:\\ 0\\.012745466401120259\ \(0\)\
\-\ vats\\:\\ 0\\.012745466401120259\ \(0\)\
\-\ overload\\:\\ 0\\.012232033398248455\ \(0\)\
\-\ illnesses\\:\\ 0\\.012232033398248455\ \(0\)\
\-\ lavage\\:\\ 0\\.01208700801242904\ \(0\)\
\-\ lymphangioleiomyomatosis\\:\\ 0\\.01208700801242904\ \(0\)\
\-\ chest\\:\\ 0\\.012004279843781909\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.011988046125795949\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.011951992608344985\ \(0\)\
\-\ asbestosis\\:\\ 0\\.011951992608344985\ \(0\)\
\-\ society\\:\\ 0\\.011951992608344985\ \(0\)\
\-\ yielded\\:\\ 0\\.011707054950900747\ \(0\)\
\-\ becoming\\:\\ 0\\.011707054950900747\ \(0\)\
\-\ \\%\\:\\ 0\\.01170247182003527\ \(0\)\
\-\ electrolytes\\:\\ 0\\.011595198955127855\ \(0\)\
\-\ liver\\:\\ 0\\.011531199651008702\ \(0\)\
\-\ does\\:\\ 0\\.011411432760798458\ \(0\)\
\-\ stains\\:\\ 0\\.011389013992979466\ \(0\)\
\-\ 10\\-15\\:\\ 0\\.011389013992979466\ \(0\)\
\-\ lower\\:\\ 0\\.011282947569650856\ \(0\)\
\-\ type\\:\\ 0\\.011274458819361684\ \(0\)\
\-\ areas\\:\\ 0\\.011253804975522766\ \(0\)\
\-\ followed\\:\\ 0\\.011212821414398323\ \(0\)\
\-\ lymphangitic\\:\\ 0\\.011115507256433167\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.011115507256433167\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.011115507256433167\ \(0\)\
\-\ lfts\\:\\ 0\\.011032220339762332\ \(0\)\
\-\ measurement\\:\\ 0\\.010952333853421325\ \(0\)\
\-\ albumin\\:\\ 0\\.010801725162352581\ \(0\)\
\-\ \\-\\:\\ 0\\.010753787428816223\ \(0\)\
\-\ pa\\/lat\\:\\ 0\\.010730555604288245\ \(0\)\
\-\ should\\:\\ 0\\.010662264351815264\ \(0\)\
\-\ histologic\\:\\ 0\\.010595540200204192\ \(0\)\
\-\ accounts\\:\\ 0\\.01053137224947427\ \(0\)\
\-\ chf\\:\\ 0\\.010469241724396812\ \(0\)\
\-\ gram\\:\\ 0\\.010350602542759954\ \(0\)\
\-\ initiated\\:\\ 0\\.010293875464730106\ \(0\)\
\-\ palliative\\:\\ 0\\.01018512820219623\ \(0\)\
\-\ organisms\\:\\ 0\\.010132939851741903\ \(0\)\
\-\ detect\\:\\ 0\\.010132939851741903\ \(0\)\
\-\ tobacco\\:\\ 0\\.010082107197332392\ \(0\)\
\-\ cancers\\:\\ 0\\.010082107197332392\ \(0\)\
\-\ bilirubin\\:\\ 0\\.010082107197332392\ \(0\)\
\-\ brain\\:\\ 0\\.010063998134257384\ \(0\)\
\-\ patient\\:\\ 0\\.01005783089138616\ \(0\)\
\-\ her\\:\\ 0\\.010056405708355911\ \(0\)\
\-\ sle\\:\\ 0\\.009984239446697045\ \(0\)\
\-\ whole\\:\\ 0\\.009846044598920228\ \(0\)\
\-\ exertion\\:\\ 0\\.00980206640742892\ \(0\)\
\-\ or\\:\\ 0\\.00979963550845115\ \(0\)\
\-\ wheezing\\:\\ 0\\.00967576793162154\ \(0\)\
\-\ estimated\\:\\ 0\\.00967576793162154\ \(0\)\
\-\ completed\\:\\ 0\\.009635417076038887\ \(0\)\
\-\ vertebrae\\:\\ 0\\.009635417076038887\ \(0\)\
\-\ syndrome\\:\\ 0\\.009565192081153195\ \(0\)\
\-\ collagen\\:\\ 0\\.009519128581966869\ \(0\)\
\-\ creatinine\\:\\ 0\\.009519128581966869\ \(0\)\
\-\ fluid\\:\\ 0\\.009505436808625648\ \(0\)\
\-\ all\\:\\ 0\\.009459583128889592\ \(0\)\
\-\ sensitivity\\:\\ 0\\.009445272754211788\ \(0\)\
\-\ contrast\\-enhanced\\:\\ 0\\.009374103196147452\ \(0\)\
\-\ scan\\:\\ 0\\.009363097692496979\ \(0\)\
\-\ performed\\:\\ 0\\.00932515980910888\ \(0\)\
\-\ ruled\\:\\ 0\\.009305431337416984\ \(0\)\
\-\ modality\\:\\ 0\\.009174919841333477\ \(0\)\
\-\ ra\\:\\ 0\\.009143608018737702\ \(0\)\
\-\ sites\\:\\ 0\\.00911278931625602\ \(0\)\
\-\ ast\\:\\ 0\\.00908244844240873\ \(0\)\
\-\ alt\\:\\ 0\\.00908244844240873\ \(0\)\
\-\ death\\:\\ 0\\.0090231424747075\ \(0\)\
\-\ lobe\\:\\ 0\\.008999316430229096\ \(0\)\
\-\ progressively\\:\\ 0\\.00899415013461916\ \(0\)\
\-\ managed\\:\\ 0\\.00899415013461916\ \(0\)\
\-\ up\\:\\ 0\\.008993530923891284\ \(0\)\
\-\ survival\\:\\ 0\\.0089655810555171\ \(0\)\
\-\ complained\\:\\ 0\\.008828675794055435\ \(0\)\
\-\ primarily\\:\\ 0\\.00877648744360111\ \(0\)\
\-\ evidence\\:\\ 0\\.00876885551219913\ \(0\)\
\-\ patients\\:\\ 0\\.008655869273448242\ \(0\)\
\-\ bacterial\\:\\ 0\\.00855746999506102\ \(0\)\
\-\ a\\:\\ 0\\.008537373424666563\ \(0\)\
\-\ relief\\:\\ 0\\.008534581463234815\ \(0\)\
\-\ \\(\\:\\ 0\\.008481742382511082\ \(0\)\
\-\ viral\\:\\ 0\\.00842399005371751\ \(0\)\
\-\ \\)\\:\\ 0\\.008378133371193405\ \(0\)\
\-\ chills\\:\\ 0\\.008360515932869851\ \(0\)\
\-\ five\\:\\ 0\\.008339807304042969\ \(0\)\
\-\ symptoms\\:\\ 0\\.008335254312712873\ \(0\)\
\-\ increased\\:\\ 0\\.008181936523677713\ \(0\)\
\-\ denied\\:\\ 0\\.008143949263814041\ \(0\)\
\-\ women\\:\\ 0\\.008125399862728828\ \(0\)\
\-\ fungal\\:\\ 0\\.008107024636995287\ \(0\)\
\-\ spread\\:\\ 0\\.008088820346070995\ \(0\)\
\-\ serum\\:\\ 0\\.00807078383901635\ \(0\)\
\-\ invasion\\:\\ 0\\.008052912051221295\ \(0\)\
\-\ leading\\:\\ 0\\.008000255587581521\ \(0\)\
\-\ american\\:\\ 0\\.00796592230059344\ \(0\)\
\-\ fevers\\:\\ 0\\.007948978929276191\ \(0\)\
\-\ be\\:\\ 0\\.007736340841549486\ \(0\)\
\-\ was\\:\\ 0\\.007736027571144319\ \(0\)\
\-\ having\\:\\ 0\\.00768134891535175\ \(0\)\
\-\ must\\:\\ 0\\.007623361053108362\ \(0\)\
\-\ were\\:\\ 0\\.007594075681760943\ \(0\)\
\-\ nodes\\:\\ 0\\.007553212067250953\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.007539479048349493\ \(0\)\
\-\ cbc\\:\\ 0\\.007472223385914644\ \(0\)\
\-\ reveal\\:\\ 0\\.007445955244364466\ \(0\)\
\-\ recurrence\\:\\ 0\\.007295346553295722\ \(0\)\
\-\ not\\:\\ 0\\.0072494246873303445\ \(0\)\
\-\ atypical\\:\\ 0\\.007247613768316937\ \(0\)\
\-\ have\\:\\ 0\\.0072424190934054465\ \(0\)\
\-\ total\\:\\ 0\\.007201017586920227\ \(0\)\
\-\ enhanced\\:\\ 0\\.007155505136500918\ \(0\)\
\-\ measures\\:\\ 0\\.007155505136500918\ \(0\)\
\-\ for\\:\\ 0\\.007134130612942418\ \(0\)\
\-\ stage\\:\\ 0\\.007133139782638642\ \(0\)\
\-\ mediastinal\\:\\ 0\\.007100063831948616\ \(0\)\
\-\ right\\:\\ 0\\.007057782458789954\ \(0\)\
\-\ bones\\:\\ 0\\.00705681462059702\ \(0\)\
\-\ shortness\\:\\ 0\\.007035543246356504\ \(0\)\
\-\ history\\:\\ 0\\.006928852471861546\ \(0\)\
\-\ after\\:\\ 0\\.006919769873225841\ \(0\)\
\-\ initially\\:\\ 0\\.0068062237656852835\ \(0\)\
\-\ lymph\\:\\ 0\\.006750572228854494\ \(0\)\
\-\ extensive\\:\\ 0\\.006687584584048425\ \(0\)\
\-\ symptomatic\\:\\ 0\\.006643803179440728\ \(0\)\
\-\ use\\:\\ 0\\.006609469892452647\ \(0\)\
\-\ is\\:\\ 0\\.006602240059311847\ \(0\)\
\-\ necrosis\\:\\ 0\\.006600979869754804\ \(0\)\
\-\ also\\:\\ 0\\.006593423067202157\ \(0\)\
\-\ worsening\\:\\ 0\\.0065841095311170205\ \(0\)\
\-\ rate\\:\\ 0\\.006518045969620045\ \(0\)\
\-\ previous\\:\\ 0\\.006493836005231499\ \(0\)\
\-\ thoracic\\:\\ 0\\.006446296489440805\ \(0\)\
\-\ skin\\:\\ 0\\.006422952906534203\ \(0\)\
\-\ cough\\:\\ 0\\.006407543794144955\ \(0\)\
\-\ based\\:\\ 0\\.006377084857665284\ \(0\)\
\-\ effusion\\:\\ 0\\.0063545477890516655\ \(0\)\
\-\ commonly\\:\\ 0\\.0063102376584259125\ \(0\)\
\-\ greater\\:\\ 0\\.006281245318337575\ \(0\)\
\-\ has\\:\\ 0\\.006280626107609698\ \(0\)\
\-\ breath\\:\\ 0\\.006252676239235515\ \(0\)\
\-\ breast\\:\\ 0\\.0061693893225646815\ \(0\)\
\-\ diagnosed\\:\\ 0\\.006149109895880637\ \(0\)\
\-\ abnormalities\\:\\ 0\\.006142396519957371\ \(0\)\
\-\ middle\\:\\ 0\\.00611577097777385\ \(0\)\
\-\ iv\\:\\ 0\\.00610259283260488\ \(0\)\
\-\ including\\:\\ 0\\.006038001254389283\ \(0\)\
\-\ did\\:\\ 0\\.006038001254389283\ \(0\)\
\-\ later\\:\\ 0\\.006038001254389283\ \(0\)\
\-\ weight\\:\\ 0\\.005994023062897974\ \(0\)\
\-\ involving\\:\\ 0\\.005867724587090594\ \(0\)\
\-\ labs\\:\\ 0\\.0058159960996773735\ \(0\)\
\-\ underwent\\:\\ 0\\.00573815271130767\ \(0\)\
\-\ elevated\\:\\ 0\\.005673808926338675\ \(0\)\
\-\ less\\:\\ 0\\.005663287679692137\ \(0\)\
\-\ cause\\:\\ 0\\.00565804819286099\ \(0\)\
\-\ three\\:\\ 0\\.005637229409680842\ \(0\)\
\-\ out\\:\\ 0\\.005526524220858153\ \(0\)\
\-\ showed\\:\\ 0\\.005482980954840893\ \(0\)\
\-\ vascular\\:\\ 0\\.005482980954840893\ \(0\)\
\-\ disease\\:\\ 0\\.005466683135873597\ \(0\)\
\-\ body\\:\\ 0\\.005431044447532455\ \(0\)\
\-\ several\\:\\ 0\\.005375915529789408\ \(0\)\
\-\ further\\:\\ 0\\.005317894602348842\ \(0\)\
\-\ and\\:\\ 0\\.005284021694683516\ \(0\)\
\-\ during\\:\\ 0\\.005117434931357745\ \(0\)\
\-\ diffuse\\:\\ 0\\.005062636830480068\ \(0\)\
\-\ month\\:\\ 0\\.005016858201175361\ \(0\)\
\-\ treated\\:\\ 0\\.005005578935584851\ \(0\)\
\-\ primary\\:\\ 0\\.0049537852502851195\ \(0\)\
\-\ in\\:\\ 0\\.004947912682664441\ \(0\)\
\-\ 5\\:\\ 0\\.004892681844313431\ \(0\)\
\-\ evaluation\\:\\ 0\\.004857610167958527\ \(0\)\
\-\ loss\\:\\ 0\\.004854137323812993\ \(0\)\
\-\ level\\:\\ 0\\.004819743694025307\ \(0\)\
\-\ of\\:\\ 0\\.004787827430054319\ \(0\)\
\-\ lymphoma\\:\\ 0\\.004779253687650657\ \(0\)\
\-\ focal\\:\\ 0\\.004775917033538947\ \(0\)\
\-\ abnormal\\:\\ 0\\.004769260744256186\ \(0\)\
\-\ edema\\:\\ 0\\.004729791564444796\ \(0\)\
\-\ chronic\\:\\ 0\\.004710351532107632\ \(0\)\
\-\ ct\\:\\ 0\\.004678292185487447\ \(0\)\
\-\ secondary\\:\\ 0\\.00467520541391156\ \(0\)\
\-\ an\\:\\ 0\\.004624911406202465\ \(0\)\
\-\ the\\:\\ 0\\.004599291271940584\ \(0\)\
\-\ are\\:\\ 0\\.004559193238863411\ \(0\)\
\-\ presented\\:\\ 0\\.004558429814133873\ \(0\)\
\-\ one\\:\\ 0\\.004531763959512023\ \(0\)\
\-\ therapy\\:\\ 0\\.004470921323367148\ \(0\)\
\-\ \\:\\:\\ 0\\.004423776187830391\ \(0\)\
\-\ than\\:\\ 0\\.004381700303166876\ \(0\)\
\-\ who\\:\\ 0\\.004360016456245992\ \(0\)\
\-\ bone\\:\\ 0\\.004155449474481154\ \(0\)\
\-\ physical\\:\\ 0\\.004102750038319449\ \(0\)\
\-\ tissue\\:\\ 0\\.003963642247461045\ \(0\)\
\-\ imaging\\:\\ 0\\.003917952689736991\ \(0\)\
\-\ posterior\\:\\ 0\\.0038544785688893316\ \(0\)\
\-\ small\\:\\ 0\\.0038523978167927953\ \(0\)\
\-\ mri\\:\\ 0\\.0038420271133358507\ \(0\)\
\-\ it\\:\\ 0\\.003758998795563633\ \(0\)\
\-\ contrast\\:\\ 0\\.0037432009526573488\ \(0\)\
\-\ exam\\:\\ 0\\.0036736476319951823\ \(0\)\
\-\ but\\:\\ 0\\.003566542663470719\ \(0\)\
\-\ findings\\:\\ 0\\.00355936778041088\ \(0\)\
\-\ female\\:\\ 0\\.003437887028273647\ \(0\)\
\-\ no\\:\\ 0\\.003367687478292767\ \(0\)\
\-\ within\\:\\ 0\\.003190081034023643\ \(0\)\
\-\ which\\:\\ 0\\.003121613673664479\ \(0\)\
\-\ on\\:\\ 0\\.0028332329251093075\ \(0\)\
\-\ as\\:\\ 0\\.002529505882375984\ \(0\)\
\-\ to\\:\\ 0\\.002507249168941211\ \(0\)\
\-\ there\\:\\ 0\\.0024886801496379423\ \(0\)\
\-\ with\\:\\ 0\\.0022897099039117363\ \(0\)\
\-\ this\\:\\ 0\\.0018808947422977163\ \(0\)\
\-\ year\\:\\ 0\\.0018710474936847645\ \(0\)\
\-\ \\.\\:\\ 0\\.0015283557615295852\ \(0\)\
